Compare Recursion Pharmaceuticals Inc (RXRX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tripadvisor Inc Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Tripadvisor Inc Common Stock trades at $10.63 (market cap $1.28B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | TRIP | |
|---|---|---|
Market Cap | $1.81B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $19.14 |
52-Week Low | $2.84 | $9.24 |
Enterprise Value | $1.33B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Tripadvisor (TRIP) trades at $10.59, down 1.76% on the day, with a bearish technical signal and recent earnings misses. The company reported Q2 2026 EPS of $0.35, below the $0.42 estimate (Zacks Investment Research, 2026-08-06). Revenue was $1.89B in 2025, with net income improving to $40M. Analyst consensus is a $13.29 price target, but sentiment is mixed with 62.5% hold ratings. The sale of TheFork for $700M provides cash but highlights competitive pressures from AI travel tools.
The outlook is cautious; while valuation ratios like P/S of 0.72 appear attractive, weak profitability and competitive threats from AI-driven platforms pose significant risks. Near-term catalysts include TheFork sale proceeds and Viator's performance, but investor sentiment remains neutral amid earnings volatility and macro headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
